Higher dose hormone therapy aims to control rare calcium disorder
Disease control
Recruiting now
This phase 3 trial tests higher daily doses (over 30 mcg) of palopegteriparatide (Yorvipath) in 36 adults with chronic hypoparathyroidism. Participants already on the drug will have their dose adjusted to find the best level for controlling calcium without needing extra vitamin D…
Phase: PHASE3 • Sponsor: Ascendis Pharma Bone Diseases A/S • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC